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Abstract
Aromatase inhibitors have been introduced as a new treatment modality that could challenge clomiphene citrate
as an ovulation induction regiment in patients with PCOS. Although several randomized trials have been
conducted regarding their use as ovulation induction agents, only few trials are available regarding their efficacy in
IVF stimulated cycles. Current available evidence support that letrozole may have a promising role in stimulated IVF
cycles, either when administered during the follicular phase for ovarian stimulation. Especially for women with poor
ovarian response, letrozole appears to have the potential to increase clinical pregnancy rates when combined with
gonadotropins, whereas at the same time reduces the total gonadotropin dose required for ovarian stimulation.
However, given that in all of the trials letrozole has been administered in GnRH antagonist cycles, it is intriguing to
test in the future how it may perform when used in GnRH agonist cycles. Finally administration of letrozole during
luteal phase in IVF cycles offers another treatment modality for patients at high risk for OHSS taking into account
that it drastically reduces estradiol levels
Background
Aromatase inhibitors are drugs traditionally used for the
treatment of hormone responsive advanced breast can-
cer [1]. The last decade several reports have supported
these agents and potential drugs for ovulation induction.
Aromatase inhibitors inhibit the aromatization of andro-
gens into oestrogens; in this regard, the hypothalamic-
pituitary axis is released from the negative estrogenic
feedback leading to increased follicular growth [2,3],
whereas the increase of intraovarian androgens enhances
early follicular growth may result in improved IVF out-
come [4]. Furthermore, considering the short half life of
these agents (~45 hours), their antiestrogenic effect dur-
ing the late follicular phase is significantly reduced
resulting improved endometrial thickness.
Several trials have tested the effect of AIs (letrozole or
anastrozole) in women with anovulatory [5] or unex-
plained infertility [6], as a co-treatment in IVF/ICSI
cycles, alone or in combination with other ovulation
induction agents and in different treatment schedules or
doses [7]. Despite the fact that these agents appear pro-
mising as ovulation induction agents, AIs have not been
yet introduced in clinical practice, either because they
do not appear to significantly enhance pregnancy rates
compared to the current clinical practice, or simply due
to the lack of large well designed randomized trials with
positive results [8].
This lack of strong evidence is even greater regarding
the use of AIs in IVF/ICSI cycles. Only few randomized
trials, with limited series of patients, have been con-
ducted up to date and the main research interest has
been accumulated in the effect of letrozole in the treat-
ment of poor responders.
Follicular phase Aromatase Inhibitors use
Normoresponders
Only one randomized trial has been conducted up-to-
date that evaluated the addition of letrozole in patients
with normal ovarian response undergoing IVF or ICSI
[9]. Despite the fact that both implantation and
ongoing pregnancy rates were higher in the letrozole
co-treatment group the results were not significant dif-
ferent, owing mainly to the small sample size and the
pilot nature of the study (Table 1). Nonetheless, letro-
zole co-treatment appeared to significantly augment
endometrial thickness compared to FSH, an observa-
tion which may indeed explain both the increased
implantation and ongoing pregnancy rates observed in
these patients.
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Poor responders
Only four randomized trials have been published
through 2010 with a total of 235 patients with poor
ovarian response randomized to receive letrozole com-
bined with gonadotropins or gonadotropins alone as
ovarian stimulation protocols in IVF/ICSI cycles (Table
1). The gonadotrophin dose used was consistently
lower in the letrozole co-treatment group in all of the
trials.
The first small randomized trial published in 2004
examined the use of letrozole as part of a low-cost IVF
protocol for poor responders. According to this study,
letrozole+ rFSH resulted in comparable pregnancy rates
with patients treated with a GnRH agonist and rFSH
alone [10]. In addition in 2 trials in which pituitary
downregulation in both treatment groups (gonadotro-
pins alone or gonadotropins co-administed with letro-
zole) was performed with the use of a GnRH antagonist
[4,11], letrozole co-treated patients experienced compar-
able pregnancy rates. On the contrary in a trial in which
different GnRH analogues were used for downregula-
tion, the administration of letrozole with FSH/HMG in
a protocol using GnRH antagonists resulted in signifi-
cantly lower implantation and fertilization rates, and sig-
nificantly lower MII oocytes and top quality embryos
compared to a microdose GnRH agonist protocol with
FSH or HMG [12]. In accordance, a prospective, non-
randomized, controlled trial [13] supported that ongoing
pregnancy rates were significantly lower in the GnRH
antagonist FSH+HMG+letrozole treatment group com-
pared to GnRH agonist FSH+HMG group.
Luteal phase aromatase inhibitors
The first randomized pilot study assessing the effect of
administration of letrozole during the luteal phase of sti-
mulated IVF cycles in oocyte donors was published in
2008 [14]. Despite the small number of patients included
and the pilot design study serum estradiol levels were sig-
nificantly lower in patients receiving letrozole compared
to controls 4, 7 or 10 days after the hCG administration.
Nonetheless, no difference in LH levels was observed
among treatment and control groups (Table 2).
Another randomized placebo controlled trial has
tested the same hypothesis in 30 egg donors after oocyte
retrieval (Table 2). Administration of 2.5 mg letrozole
for 5 days from the day of ovum pick-up, significantly
reduced serum E2 levels at 4, 7 and 10 days after oocyte
retrieval compared to placebo in accordance to the
study by Fatemi et al. However, letrozole appeared to
significantly increased LH levels on days 7 and 10 after
retrieval [15].
Both randomized trials provided evidence that letro-
zole drastically reduces E2 levels whereas the trial Gar-
cia-Velasco et al., demonstrated that letrozole restores
LH secretion sooner in egg donors. In this regard AIs
may be of interest not only for egg donors but also in
patients at high risk of OHSS who freeze their oocytes/
embryos or cancel hCG administration in order to
reduce the risk linked to elevated estadiol levels.
Aromatase inhibitors in cancer patients
The last five years letrozole has been introduced as an
agent that could be used in cancer patients undergoing
Table 1 Available randomized trials regarding the use of letrozole during the follicular phase in IVF/ICSI cycles
Pituitary
downregulation
protocol/groups
Ovarian
stimulation
Patients
(N)
Clinical
pregnancy
rate (%)
Implantation
rate (%)
Fertilization
rate (%)
No
oocytes
(mean)
Total FSH
dose (mean)
Normoresponders
Verpoest 2006
[9]
Antagonist rFSH
+letrozole
10 50 31.25 63.3 13.8 1575
Antagonist rFSH 10 20 12.5 77.4 9.6 1650
Poor responders
Goswami 2004
[10]
- rFSH
+letrozole
13 23 NA NA 1.6 150
Agonist rFSH 25 24 NA NA 2.1 2865
Garcia-Velasco
2005 [4]
Antagonist rFSH+ HMG
+ letrozole
71 22.4 25 68.2 6.1 3627
Antagonist rFSH+ HMG 76 15.2 9.4 63.3 4.3 3804
Ozmen 2009
[11]
Antagonist rFSH
+letrozole
35 28.6 NA 92.4 4.9 2980
Antagonist rFSH 35 17.1 NA 97.2 4.8 3850
Davar 2010
[12]
Antagonist rFSH/HMG
+ letrozole
45 4.4 3.8 67.3 2.8 3158
Agonist rFSH or
HMG
49 12.3 7.7 70.7 4.4 3458
N, number; NA, not data available
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ovarian stimulation in order to preserve fertility prior
chemotherapy, through embryo or oocyte cryopreserva-
tion [16]. The beneficial effect of letrozole has been
underlined through several observation studies which
supported that when used in ovarian stimulation it
results in significantly lower estrogen exposure [17,18].
GnRh agonist triggering in these patients may also have
beneficial effects when combined with stimulation with
letrozole, since in results in significantly lower post-trig-
gering estradiol levels [19]. However, the most impor-
tant observation is that stimulation with letrozole and
gonadotropins is unlikely to increase recurrence risk in
cancer patients [20].
Current practice and future implications
At the moment existing evidence for the use of aroma-
tase inhibitors as part of an IVF/ICSI protocol is frag-
mented and weak. Despite the timeframe of ten years
since introduction of AIs as ovulation induction agents,
few randomized trials with limited number of patients
have been conducted up to date. The lack of solid evi-
dence in this field has been previously underlined [8],
and definitely prevent us from introducing these evi-
dence in clinical practice.
Based on the available data it appears that scant scienti-
fic evidence exists regarding the role of letrozole during
the follicular phase women with normal ovarian
response. However, letrozole may serve as an alternative
for patients with poor ovarian response. A very important
observation from the available data, is that a treatment
protocol with GnRH antagonists, letrozole and gonado-
trophins, hints a danger for compromising clinical preg-
nancy rates compared to treatment with gonadotropins
in a microdose GnRH agonist protocol. Nonetheless,
these negative results should not necessarily be attributed
to letrozole, but may indeed be related to the type of ana-
logue used. Microdose GnRH agonist flare protocols have
been shown to be an effective treatment for poor respon-
ders, with randomized trials supporting significantly
higher implantation rates compared to GnRH antagonist
protocols [21,22]. Consequently, future trials may need
to test whether AIs combined with gonadotropins may
be comparable with gonadotropins alone in protocols
involving GnRH agonists only. Taking into account that
the dose of gonadotropins and the cost is significantly
lower whenever letrozole is used, such an approach may
be the most realistic cost effective way to treat women
with poor ovarian reserve. Nonetheless, this needs to be
replicated by large well designed trials.
Furthemore, the administration of letrozole during the
luteal phase offers a new insight for patients at high risk
for OHSS. Despite the fact that the results are based
solely on one randomized trial, if they are confirmed by
future studies letrozole may have a role as a preventive
measure for OHSS.
Although a trial published by Tulandi et al. in 2006
[23] supported the safety of letrozole for the newborns,
it should be noted that letrozole has not yet received an
official permission in order to be administered in pre-
menopausal patients as an ovulation induction agent.
Therefore any use is off-label.
Conclusions
Current evidence supports aromatase inhibitors can be a
safe solution for fertility preservation in cancer patients
prior chemotherapy. Although letrozole may have a role
in the treatment of poor responder patients, results are
based on few evidence and need to be replicated in the
future, whereas its use in normoresponders requires
even more intensive research. Their use should also
include the long agonist protocol for IVF, as this proto-
col is widely used. Off label inscription shall be re-evalu-
ated from pharmaceutical industry and reproductive
associations in order more appropriate randomized stu-
dies to be performed.
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Luteal phase
supplementation
Days of
administration
Patients
(N)
Serum estradiol
levels (mean values)
LH levels
(mean values)
LUTEAL PHASE Day
4
Day
7
Day
10
Day
4
Day
7
Day
10
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OPU, ovum pick-up
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